What question did this study set out to answer?

The study aims to evaluate the therapeutic potential of targeting BCL-XL in cholangiocarcinoma, particularly in conjunction with gemcitabine to combat treatment resistance.

February 2, 2026BMC Medicine1 citationsOpen Access

View Full Paper

Targeting BCL-XL for degradation synergizes with gemcitabine against cholangiocarcinoma

QZQinghua ZengKunming Institute of Zoology YZYan ZhangKunming Institute of Zoology YYYe YangXiamen University

Key Points

The study aims to evaluate the therapeutic potential of targeting BCL-XL in cholangiocarcinoma, particularly in conjunction with gemcitabine to combat treatment resistance.
Identified XZ739 as a candidate for BCL-XL degradation
Assessed combination effects of XZ739 with gemcitabine in cell models
Evaluated hematologic toxicity associated with treatment combinations
XZ739 effectively degraded BCL-XL in cholangiocarcinoma cells
Combination of XZ739 with gemcitabine showed enhanced anti-cancer effects
Treatment decreased hematologic toxicity compared to gemcitabine alone

Abstract

These findings establish XZ739 as a promising therapeutic candidate for BCL-XL-dependent CCA, highlighting its translational potential for rational combination with chemotherapy to overcome resistance while mitigating hematologic toxicity.

问 AI

Bookmark

View Full Paper

问 AI

Bookmark

View Full Paper

Targeting BCL-XL for degradation synergizes with gemcitabine against cholangiocarcinoma

Key Points

Abstract

Cite This Study

Also Consider

Also Consider